Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a $3 billion market cap pharmaceutical company specializing in the development of therapeutic drugs, announced today the departure of its Chief Commercial ...

Xenon has promising Phase 2 data for MDD treatment, robust financials, and a potential in niche markets, despite premium ...

Highlights,Xenon Pharmaceuticals operates within the biotechnology sector, focusing on treatments for neurological disorders.,Shares of Xenon Pharmaceuticals began trading at a price above their short ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Startups and growing companies often face the pivotal question, "Should we build a solution in-house or buy it off the shelf?" This decision significantly impacts resources, scalability and ...

Xenon Pharmaceuticals (XENE) – Price target: 63.00 This company is poised to rally in 2025, according to J.P. Morgan. “We anticipate phase 3 trials evaluating azetukalner as an adjunctive ...